Download this datacard
Overview
Lobbying Costs
17,500€
Financial year: Jan 2018 - Dec 2018
Lobbyists (Full time equivalent)
0.5 Fte (2)
Lobbyists with EP accreditation
0
High-level Commission meetings
5
Lobbying Costs over the years
-
Info
BEAM Alliance
EU Transparency Register
989919136810-31 First registered on 16 Dec 2019
Goals / Remit
Since its inception in 2016, the BEAM Alliance has succeeded in uniting European Small Medium Enterprises (SMEs) working in the field of antimicrobial resistance (AMR), SMEs are recognized as the driving force of today’s innovation in the field. The BEAM Alliance enables innovation in AMR research by giving its members a unique voice to propose and support policies and incentives in Europe that enable much needed progress in the discovery and development of novel antimicrobial solutions, including preventive, diagnostic or therapeutic approaches. Collaborating with the existing community of global stakeholders, BEAM Alliance works towards the implementation of tangible solutions that support SMEs, and by recommending bold incentives that warrant action by policymakers to stimulate sustainable innovation.
For most stakeholders in the field of AMR (including governments, patients, industry representatives and other policy makers), BEAM is now recognised as a unique contributor helping our understanding of the complex array of cross-disciplinary issues (science, finance, and policymaking). In Europe, BEAM has established channels of communication with the European Commission and Governments, and international, national and local policy makers. At a global level BEAM participates in international science and policy forums to understand and influence activities that can support the needs of its members and the challenges in developing solutions to fight AMR. Through its efforts BEAM offers SMEs the means to directly influence debate and policy making locally, nationally and internationally.Main EU files targeted
The BEAM Alliance is following any legal and regulatory actions intended to improve the current AMR market landscape. The BEAM Alliance has thus a special interest in so-called “PULL incentives” that can facilitate the market uptake of innovative solutions against AMR. PULL incentives include financial rewards, improved valuation and pricing methodologies or reimbursement mechanisms. The BEAM Alliance also has a special focus on funding instruments able to de-risk R&D activities (so-called “PUSH incentives”). From a wider perspective, the BEAM Alliance follows all evolutions linked to the fight against AMR (stewardship policies, access to critical medicine, etc.) and more generally policies related to SMEs and innovation.
Address
Head Office
Le Dorian Bât B1 C/O Da Volterra
172 Rue de Charonne
Paris 75011
FRANCE -
People
Total lobbyists declared
2
Employment time Lobbyists 25% 2 Lobbyists (Full time equivalent)
0.5
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
Apart from the dedicated staff mentioned above, elected Board Members (7-8) and one coordinator (see https://beam-alliance.eu/ for details), all with active executive positions in their own companies, are contributing pro-bono to the BEAM Alliance actions.
Person in charge of EU relations
Mr Frederic PEYRANE (Senior Project manager and Public affairs)
Person with legal responsibility
Ms Florence SEJOURNE (President)
-
Categories
Category
II - In-house lobbyists and trade/business/professional associations
Subcategory
Trade and business associations
-
Networking
Affiliation
The BEAM Alliance is a member of the AMR Industry Alliance (https://www.amrindustryalliance.org)
Member organisations
The BEAM Alliance has members from 3 types. Full members are private or public pure player SMEs developing products focused upon prevention, diagnosis and cure of microbial infections. Headquarters and main activities are located in Europe. International members have similar profile but only part of their activity takes place in Europe. Associated members are private or public actors developing activities against AMR such as services, R&D, etc. The updated list of current members is available here: https://beam-alliance.eu/members/
-
Financial Data
Closed financial year
Jan 2018 - Dec 2018
Lobbying costs for closed financial year
17,500€
Other financial info
The resources of the BEAM Alliance are mainly based on membership fees that are rather limited, owing to the small size of our members and the difficult economic context in the AMR field. A grant awarded by the JPIAMR and funded by the French ANR is completing the association’s income. The expenses are mainly dedicated to staff wages and some travels to attend meetings and conference.
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
None
Communication activities
As part of its activities, the BEAM Alliance is in constant interactions with stakeholders involved in the fight against AMR at the international (WHO, UN IACG, European Commission, EMA, ESCMID, EUCAST, Global AMR R&D Hub, etc.) and national (ministries of health) levels. The BEAM Alliance is mainly delivering its vision and propositions through position papers (https://beam-alliance.eu/our-actions/) and invited speakers to conferences and forums, such as the AMR conference (https://amr-conference.com/).
Other activities
None declared
Meetings
Meetings
5 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 08 Jun 2023 Location Brussels Subject Discussions on push incentives models for antibiotics DG Health Emergency Preparedness and Response Authority Attending - Pierre Delsaux (Director-General)
-
Date 29 Jun 2022 Location Brussels Subject VTC meeting on Revision of the pharmaceutical legislation and Anti-microbial resistance. Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Karolina Herbout-Borczak (Cabinet member)
- Annukka Ojala (Cabinet member)
-
Date 18 Jan 2022 Location VIRTUAL MEETING Subject To discuss HERA DG Health Emergency Preparedness and Response Authority Attending - Pierre Delsaux (Director-General)
-
Date 01 Oct 2020 Location Brussels Subject Virtual meeting about the Antimicrobial Resistance Cabinet Cabinet of Commissioner Stella Kyriakides Portfolio Health Attending - Annukka Ojala (Cabinet member)
-
Date 11 Sep 2020 Location Videoconference Subject Challenges faced by EU SME in the anti-microbial resistance field and the upcoming pharmaceutical strategy. Cabinet Cabinet of Commissioner Thierry Breton Portfolio Internal Market Attending - Eszter Batta (Cabinet member)